


CLAIMS


What is claimed is:

1. A compound, including enantiomers, stereoisomers and tautomers thereof, or pharmaceutically acceptable salts or solvates of said compound, with
- 5 said compound having the general structure shown in Formula I:



Formula I

M is a moiety having a general structure shown in Formula II or III:




- 10 where $k = 0$ or 1 , $n = 0-5$, and $p = q = 0, 1$ or 2 with the proviso that when M is Formula III, R^3 is absent;
- V is a moiety selected from the group consisting of C_1-C_8 alkyl; $-(CH_2)_x-A-(CH_2)_y-$; and $-(CH_2)_c-A-(CH_2)_m-C(O)-N(R^7)-(CH_2)_d-$, where A is $-O-$, $-S(O)_r-$, and $-NR^7-$; $m = 0, 1, 2$ or 3 ; x is a whole number in the range $2-8$; y is a whole number in
- 15 the range $1-5$; c is a whole number in the range $2-4$; and $r = 0, 1$ or 2 ; d is a number in the range $0-5$;
- X and Y are independently selected from the group consisting of N, CH, and N(O);
- Z is selected from the group consisting of N, CH and N(O);
- 20 R^1 and R^2 may each number $1-4$ and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, polyhalolower alkyl, polyhalolower alkoxy, $-OH$, CN , NO_2 , or $COOR^8$;

R^3 is selected from hydrogen, lower alkyl, lower alkoxy, hydroxyl, with the proviso that when n and k are both 0, then R^3 is not -OH or alkoxy;


R^4 is selected from the group consisting of hydrogen, lower alkyl, polyhalolower alkyl or -OH; and

- 5 R^7 and R^8 are independently selected from hydrogen, lower alkyl, substituted or unsubstituted phenyl; and substituted or unsubstituted benzyl.
2. The compound of claim 1, wherein R^4 is H.
3. The compound of claim 2, wherein R^1 and R^2 are independently selected from H, halogen, or polyhalolower alkyl.
- 10 4. The compound of claim 1, wherein M is:



and p and q are independently 0 or 1.

5. The compound of claim 1, wherein M is:



- 15 and $p = q = 1$.

6. The compound of claim 4, wherein R^4 is H; $R^1 = R^2 = H$, halogen, hydroxy or alkoxy; and R^3 is H or lower alkyl.
7. The compound of Claim 6, wherein $V = C_1 - C_8$ alkyl.
- 20 8. The compound of claim 5, wherein R^4 is H; and $R^1 = R^2 = H$, halogen, hydroxy or alkoxy.
9. The compound of Claim 8, wherein V is $C_1 - C_8$ alkyl.
10. A pharmaceutical composition comprising as an active ingredient a compound of claim 1.
- 25 11. A pharmaceutical composition for use in treating inflammation, allergy, allergic rhinitis, nasal congestion, diseases of the GI-tract, cardiovascular

disease, or disturbances of the central nervous system as well as allergy-induced airway responses, nasal congestion and obesity, said composition comprising as an active ingredient a compound of claim 1.


12. The pharmaceutical composition of claim 10 additionally comprising a pharmaceutically acceptable carrier.

13. A method of treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 1.


14. The use of a compound of claim 1 for the manufacture of a medicament for the treatment of inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity.









15. A method of preparing a pharmaceutical composition for treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.


16. A compound exhibiting H₃ antagonist activity, including enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:



17. A compound exhibiting both H₁ and H₃ antagonist activity, including enantiomers, stereoisomers and tautomers of said compound, or
- 5 pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:







18. A pharmaceutical composition for treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.